18F-Pentixafor PET in Hematologic Malignancies

Recruiting now

Conditions studied: Hematological Malignancies

In brief

The aim of this study is to evaluate the efficacy of 18F-Pentixafor PET imaging in the diagnosis, staging and response evaluation of hematological malignancies.

Key facts

Study ID

NCT07122674

Run by

First Affiliated Hospital of Zhejiang University

People needed

100

Starts

2025-07-01

Expected to finish

2029-12-01

Last updated by the study team

2025-08-14

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age of 18-80 years old, both sexes, with behavioral capacity;
• patients with suspected or confirmed hematological malignancies;
• 18F-FDG PET or other imaging examinations should be performed according to the treatment plan;
• For suspected patients, biopsy or needle biopsy is expected to obtain pathological results;
• Can provide informed consent, can understand and comply with the requirements of the study.

You may not qualify if…

• pregnant and lactating women;
• patients with fear or radiophobia, or with mental disorder or primary affective disorder;
• received ionizing radiation outside the scope of this study for clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 mSv;
• received investigational drugs or devices of uncertain efficacy or safety within 1 month;
• Any condition that the chairpersons of the study consider that any link related to the study may cause harm or have potential harm.

Where it is running

• The First Affiliated Hospital of Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.